Tigecycline in critical care

Praveen K Mullangi; George A Pankey

doi:10.1016/j.ccc.2007.12.007

Tigecycline in critical care

Crit Care Clin. 2008 Apr;24(2):365-75, x. doi: 10.1016/j.ccc.2007.12.007.

Authors

Praveen K Mullangi¹, George A Pankey

Affiliation

¹ Department of Infectious Diseases, Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA.

PMID: 18361951
DOI: 10.1016/j.ccc.2007.12.007

Abstract

The emergence and spread of multidrug resistance in many pathogenic bacterial species is increasing at an alarming rate, especially with hospital-acquired infections in the critical care setting. Deaths associated with hospital-acquired infections have exceeded the number attributable to several of the top 10 leading causes of death reported in the United States. The emerging resistance limits the use of older antibiotics. Tigecycline is a new agent, and this article explores its role in the treatment of adults in the critical care setting.

Publication types

Review

MeSH terms

Adult
Anti-Bacterial Agents / pharmacokinetics
Anti-Bacterial Agents / pharmacology
Anti-Bacterial Agents / therapeutic use*
Costs and Cost Analysis
Critical Care*
Cross Infection / drug therapy*
Cross Infection / epidemiology
Cross Infection / mortality
Humans
Microbial Sensitivity Tests
Minocycline / analogs & derivatives*
Minocycline / pharmacokinetics
Minocycline / pharmacology
Minocycline / therapeutic use
Randomized Controlled Trials as Topic
Tigecycline
United States / epidemiology

Substances

Anti-Bacterial Agents
Tigecycline
Minocycline